This Page Intentionally Left Blank - Int Medical

196 Dysmenorrhea
12. Fine PG. The role of rofecoxib, a cyclooxygenase-2-specific inhibitor, for the
treatment of non-cancer pain: a review. J Pain. 2002;3(4):272–283.
13. Martina SD, Vesta KS, Ripley TL. Etoricoxib: a highly selective COX-2 inhibitor.
Ann Pharmacother. 2005;39(5):854–862.
14. Alsalameh S, Burian M, Mahr G, et al. Review article: the pharmacological
properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective
inhibitor. Aliment Pharmacol Ther. 2003;17(4):489–501.
15. Fenton C, Keating GM, Wagstaff AJ. Valdecoxib: a review of its use in the
management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and
acute pain. Drugs. 2004;64(11):1231–1261.
16. Bannwarth B, Berenbaum F. Clinical pharmacology of lumiracoxib, a secondgeneration
cyclooxygenase 2 selective inhibitor. Expert Opin Invest Drugs.
2005;14(4):521–533.
17. Cochrane DJ, Jarvis B, Keating GM. Etoricoxib. Drugs. 2002;62(18):2637–2651;
discussion 2652–2653.
18. Friedel HA, Fitton A. Flupirtine. A review of its pharmacological properties,
and therapeutic efficacy in pain states. Drugs. 1993;45(4):548–569.